Porter’s Journal

Most people think of biotech as speculative – a domain of lottery tickets and roulette-type wagers on FDA decisions. But real success here is different than that. The work lies in telling the difference between potential winners and a roll of the dice. Tech Investor editor Erez Kalir explains.

This giant, household name of a company was trading at a rare discount to its intrinsic value. Despite generating extraordinary levels of free cash flow, maintaining global search dominance, and aggressively buying back stock, the market had mispriced it. We did not. Shares soared 81% since then!

Complete Investor is the culmination of everything Porter has done and learned in his nearly three decades as a financial publisher. There is so much in store in 2026 – to make you a better investor, to make you a complete investor, and to make you a much wealthier investor.

In this issue of Saturday Stock Screen... we use a filter developed by Marty Fridson to sift through thousands of stocks to find a handful that we will then do more in-depth analysis for possible inclusion in our Complete Investor or our other portfolios.

Today, Porter completes the report-card grading of the Porter & Co. financial publications with the final three of our remaining advisories – Porter & Co.’s Asymmetry, The Trading Club, and Porter’s Permanent Portfolio.